Mercado de Síndrome de Down da Ásia-Pacífico – Tendências do setor e previsão para 2028

Pedido de resumo Pedido de TOC Fale com Analista Fale com o analista  Comprar agora Comprar agora Consulte antes Comprar Consulte antes Relatório de amostra grátis Relatório de amostra grátis

Mercado de Síndrome de Down da Ásia-Pacífico – Tendências do setor e previsão para 2028

  • Pharmaceutical
  • Publish Reports
  • Mar 2021
  • Asia-Pacific
  • 350 Páginas
  • Número de tabelas: 16
  • Número de figuras: 186

>Mercado de Síndrome de Down Ásia-Pacífico, por tipo de doença (Trissomia 21, Síndrome de Down de Translocação e Síndrome de Down em Mosaico), Tratamento (Diagnóstico e Terapia), Utilizador Final (Hospital, Clínicas, Ambiente de Homecare, Centros de Terapia e Outros), Canal de Distribuição (Concurso Directo, vendas a retalho e outros), país (China, Japão, Índia, Austrália, Coreia do Sul, Singapura, Tailândia, Malásia, Indonésia, Filipinas, Vietname e resto da Ásia-Pacífico ) Tendências e previsões da indústria para 2028

Mercado de Síndrome de Down da Ásia-PacíficoAnálise e insights de mercado: Mercado de Síndrome de Down da Ásia-Pacífico

Espera-se que o mercado da síndrome de Down ganhe crescimento de mercado no período de previsão de 2021 a 2028. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 16,2% no período de previsão de 2021 a 2028 e deverá atingir os 559,87 milhões de dólares até 2028.

O aumento da prevalência da síndrome de Down e de outras perturbações relacionadas e a presença de terapias em pipeline são os principais impulsionadores que impulsionaram a procura do mercado no período de previsão.

A síndrome de Down compreende características que a crescente necessidade de produtos seguros e eficazes irá impactar no lançamento de novos produtos pelos fabricantes no mercado que aumentam a sua procura, bem como o aumento do investimento em investigação e desenvolvimento leva ao crescimento do mercado.

Atualmente, estão a ser realizados vários estudos de investigação, que deverão criar uma vantagem competitiva para os fabricantes desenvolverem produtos novos e inovadores para a síndrome de Down, o que deverá proporcionar várias outras oportunidades no mercado da síndrome de Down. No entanto, a falta de profissionais qualificados e os efeitos secundários associados às terapias de tratamento da síndrome de Down deverão restringir o crescimento do mercado no período de previsão.

O relatório de mercado da síndrome de Down fornece detalhes da quota de mercado, novos desenvolvimentos e análise do pipeline de produtos, impacto dos participantes do mercado doméstico e localizado, analisa as oportunidades em termos de bolsas de receitas emergentes, alterações nas regulamentações do mercado , aprovações de produtos, decisões estratégicas, lançamentos de produtos, expansões geográficas e inovações tecnológicas no mercado. Para compreender a análise e o cenário do mercado contacte-nos para um resumo do analista, a nossa equipa irá ajudá-lo a criar uma solução de impacto na receita para atingir o objetivo desejado.

Mercado de Síndrome de Down da Ásia-PacíficoÂmbito do mercado global de síndrome de Down e dimensão do mercado

O mercado da síndrome de Down está categorizado em quatro segmentos notáveis ​​que se baseiam no tipo de doença, tratamento, utilizador final e canal de distribuição. O crescimento entre segmentos ajuda-o a analisar os nichos de crescimento e as estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.

  • On the basis of disease type, the Down syndrome market is segmented into trisomy 21, translocation Down syndrome and mosaic Down syndrome. In 2021, trisomy 21 is dominating the market as it is the most common type of Down syndrome among three types and accounts for about 95% of all cases.   
  • On the basis of treatment, the Down syndrome market is segmented into diagnosis and therapy. In 2021, diagnosis segment is dominating the market as most of the pregnant women are highly recommended for different types of diagnosis including prenatal testing, ultrasound among others in order to confirm the health of developing fetus.
  • On the basis of end user, the Down syndrome market is segmented into hospital, clinics, homecare setting, therapy centers and others. In 2021, hospital segment is dominating the market because hospitals are equipped with advanced diagnostic tools which allow women to achieve appropriate diagnostic results. Moreover presence of skilled professionals also enhances the accuracy of results.  
  • On the basis of distribution channel, the Down syndrome market is segmented into direct tender, retail sales and others. In 2021, direct tenders are dominating in the market as direct tender are the primary source of devices procurement and most of the healthcare facilities are largely dependent upon direct tenders for products procurement.

Down syndrome Market Country Level Analysis

The Down syndrome market is analyzed and market size information is provided on the basis of disease type, treatment, end user and distribution channel.

The countries covered in the Down syndrome market report are China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Rest of Asia-Pacific.

Asia-Pacific is expected to grow with the CAGR in the forecasted periods as in the Asia-Pacific’s countries awareness for Down syndrome is increasing very rapidly with the urbanization and availability of medical facilities. China is expected to dominate in the market in the Asia-Pacific market to due fast developing healthcare infrastructure.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Rising Awareness about The Disease and Rising Demand for Effective Therapies are boosting the Market Growth of Down Syndrome

O mercado da síndrome de Down também fornece análises de mercado detalhadas para o crescimento de cada país na indústria da síndrome de Down com vendas de medicamentos para a síndrome de Down, impacto do avanço na tecnologia da síndrome de Down e mudanças nos cenários regulamentares com o seu apoio ao mercado da síndrome de Down. Os dados estão disponíveis para o período histórico de 2011 a 2019.

Análise do panorama competitivo e da quota de mercado da Síndrome de Down

O panorama competitivo do mercado da síndrome de Down fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, pipelines de testes de produtos, aprovações de produtos, patentes, largura do produto e respiração, domínio da aplicação, curva da linha de vida da tecnologia. Os dados fornecidos acima estão apenas relacionados com o foco da empresa relacionado com o mercado da síndrome de Down.

As principais empresas que lidam com a síndrome de Down são a Natera, Inc., a Myriad Genetics, Inc., a PerkinElmer Inc., a F. Hoffmann-La Roche Ltd, a Thermo Fisher Scientific Inc., a Novus Biologicals (uma subsidiária da Bio-Techne, Kid Sense Child Development Corporation Pty Ltd, Abbott, Illumina, Inc.

Muitos lançamentos e acordos de produtos são também iniciados pelas empresas de todo o mundo que também estão a acelerar o mercado da síndrome de Down.

  • Em dezembro de 2019, o Myriad Genetics, Inc. Prequel Prenatal Screen revelou-se superior a outros rastreios tradicionais sem ADN, utilizados para a identificação de anomalias cromossómicas em mulheres grávidas. O produto desenvolvido pela empresa utiliza uma abordagem de sequenciação do genoma completo para identificar a trissomia dos cromossomas 21, 18 e 13. Esta iniciativa ajudou a empresa a obter um crescimento rentável no mercado da síndrome de Down.

A colaboração, o lançamento de produtos, a expansão do negócio, a premiação e o reconhecimento, as joint ventures e outras estratégias do player de mercado estão a potenciar o mercado da empresa no mercado da síndrome de Down, o que também oferece o benefício para a organização melhorar a sua oferta para a síndrome de Down.


SKU-

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

  • Painel interativo de análise de dados
  • Painel de análise da empresa para oportunidades de elevado potencial de crescimento
  • Acesso de analista de pesquisa para personalização e customização. consultas
  • Análise da concorrência com painel interativo
  • Últimas notícias, atualizações e atualizações Análise de tendências
  • Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Pedido de demonstração

Índice

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA-PACIFIC DOWN SYNDROME MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TREATMENT OF DOWN SYNDROME LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 ASIA-PACIFIC DOWN SYNDROME MARKET: PIPELINE ANALYSIS

4.1 PIPELINE PRODUCTS IMPACT ANALYSIS

4.2 NNI-351

4.3 ASPARAGINASE

4.4 ANVS-401

4.5 QUILLIVANT XR

4.6 TOFACITINIB

4.7 MEMANTINE HYDROCHLORIDE

4.8 NICOTINE

4.9 AEF0217

4.1 ACI-24

5 ASIA-PACIFIC DOWN SYNDROME MARKET: LAWS AND REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASING PREVALENCE OF DOWN SYNDROME

6.1.2 RISING DEMAND OF EFFECTIVE THERAPIES

6.1.3 RISING AWARENESS ABOUT THE DISEASE

6.1.4 TECHNOLOGICAL ADVANCEMENTS

6.1.5 INCREASING GOVERNMENT SUPPORT

6.2 RESTRAINTS

6.2.1 UNAVAILABILITY OF ANY SPECIFIC TREATMENT

6.2.2 SIDE EFFECTS ASSOCIATED WITH DOWN SYNDROME TREATMENT THERAPIES

6.2.3 HIGH COST OF DIAGNOSIS

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS

6.3.2 INCREASING RESEARCH AND DEVELOPMENT

6.3.3 PRESENCE OF PIPELINE THERAPIES

6.3.4 PRESENCE OF REIMBURSEMENT

6.4 CHALLENGES

6.4.1 LACK OF SKILLED PROFFESSIONALS

6.4.2 LONG PROCESS FOR PRODUCT LAUNCH

6.4.3 TRANSFER OF COVID-19 INFECTIONS BY DIAGNOSTIC METHODS

7 IMPACT OF COVID-19 ON ASIA-PACIFIC DOWN SYNDROME MARKET

7.1 PRICE IMPACT

7.2 IMPACT ON SUPPLY CHAIN

7.3 IMPACT ON DEMAND

7.4 STRATEGIC DECISIONS FOR MANUFACTURERS

7.5 CONCLUSION

8 ASIA-PACIFIC DOWN SYNDROME MARKET, BY DISEASE TYPE

8.1 OVERVIEW

8.2 TRISOMY 21

8.3 TRANSLOCATION DOWN SYNDROME

8.4 MOSAIC DOWN SYNDROME

9 ASIA-PACIFIC DOWN SYNDROME MARKET, BY TREATMENT

9.1 OVERVIEW

9.2 DIAGNOSIS

9.2.1 SCREENING TESTS

9.2.1.1 First Trimester

9.2.1.1.1 Blood Test

9.2.1.1.2 Nuchal Translucency Testing

9.2.1.2 Integrated Screening Test

9.2.1.2.1 First Trimester

9.2.1.2.2 Second Trimester

9.2.1.3 The Triple Screen or Quadraple Screen Test

9.2.1.4 Ultrasound

9.2.1.5 Cell Free DNA

9.2.2 DIAGNOSTIC TESTS

9.2.2.1 Chronic Villus Sampling

9.2.2.2 Amniocentesis

9.2.2.3 Precutaneous Umbical Cord Sampling

9.3 THERAPY

9.3.1 EARLY INTERVENTION THERAPY

9.3.1.1 Speech-Language Therapy

9.3.1.2 Physical Therapy

9.3.1.3 Occupational Therapy

9.3.1.4 Others

9.3.2 ASSISTIVE TECHNOLOGY

9.3.2.1 Hearing Aids

9.3.2.2 Glasses

9.3.2.3 Others

9.3.3 SURGERY

9.3.3.1 Atrioventricular Septal Defect (AVSD)

9.3.3.2 Duodenal Atresia

9.3.3.3 Others

9.3.4 OTHERS

10 ASIA-PACIFIC DOWN SYNDROME MARKET, BY END USER

10.1 OVERVIEW

10.2 HOSPITAL

10.3 CLINICS

10.4 HOMECARE SETTING

10.5 OTHERS

11 ASIA-PACIFIC DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL

11.1 OVERVIEW

11.2 DIRECT TENDER

11.3 RETAIL SALES

11.4 OTHERS

12 ASIA-PACIFIC DOWN SYNDROME MARKET, BY GEOGRAPHY

12.1 ASIA-PACIFIC

12.1.1 CHINA

12.1.2 JAPAN

12.1.3 AUSTRALIA

12.1.4 SOUTH KOREA

12.1.5 INDIA

12.1.6 SINGAPORE

12.1.7 THAILAND

12.1.8 MALAYSIA

12.1.9 INDONESIA

12.1.10 PHILIPPINES

12.1.11 VIETNAM

12.1.12 REST OF ASIA-PACIFIC

13 ASIA-PACIFIC DOWN SYNDROME MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

14 COMPANY PROFILE

14.1 F. HOFFMANN-LA ROCHE LTD

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 COMPANY ANALYSIS

14.1.4 PRODUCT PORTFOLIO

14.1.5 RECENT DEVELOPMENTS

14.2 PERKINELMER INC.

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 COMPANY ANALYSIS

14.2.4 PRODUCT PORTFOLIO

14.2.5 RECENT DEVELOPMENTS

14.3 ILLUMINA, INC.

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 COMPANY ANALYSIS

14.3.4 PRODUCT PORTFOLIO

14.3.5 RECENT DEVELOPMENTS

14.4 THERMO FISHER SCIENTIFIC INC.

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COMPANY ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENTS

14.5 MYRIAD GENETICS, INC.

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 COMPANY ANALYSIS

14.5.4 PRODUCT PORTFOLIO

14.5.5 RECENT DEVELOPMENTS

14.6 ABBOTT

14.6.1 COMPANY SNAPSHOT

14.6.2 REVENUE ANALYSIS

14.6.3 PRODUCT PORTFOLIO

14.6.4 RECENT DEVELOPMENTS

14.7 ABNOVA CORPORATION

14.7.1 COMPANY SNAPSHOT

14.7.2 PRODUCT PORTFOLIO

14.7.3 RECENT DEVELOPMENTS

14.8 ASDCLINIC.CO.UK

14.8.1 COMPANY SNAPSHOT

14.8.2 SERVICE PORTFOLIO

14.8.3 RECENT DEVELOPMENT

14.9 ATILABIOSYSTEMS

14.9.1 COMPANY SNAPSHOT

14.9.2 PRODUCT PORTFOLIO

14.9.3 RECENT DEVELOPMENT

14.1 BOSTON CHILDREN'S HOSPITAL

14.10.1 COMPANY SNAPSHOT

14.10.2 SERVICE PORTFOLIO

14.10.3 RECENT DEVELOPMENTS

14.11 BOYS TOWN NATIONAL RESEARCH HOSPITAL

14.11.1 COMPANY SNAPSHOT

14.11.2 SERVICE PORTFOLIO

14.11.3 RECENT DEVELOPMENTS

14.12 CHILDREN'S HOSPITAL COLORADO

14.12.1 COMPANY SNAPSHOT

14.12.2 SERVICE PORTFOLIO

14.12.3 RECENT DEVELOPMENTS

14.13 DEMEDITEC DIAGNOSTICS GMBH

14.13.1 COMPANY SNAPSHOT

14.13.2 PRODUCT PORTFOLIO

14.13.3 RECENT DEVELOPMENT

14.14 DOWN SYNDROME CORK

14.14.1 COMPANY SNAPSHOT

14.14.2 SERVICE PORTFOLIO

14.14.3 RECENT DEVELOPMENTS

14.15 MAYO CLINIC HEALTH SYSTEM

14.15.1 COMPANY SNAPSHOT

14.15.2 SERVICE PORTFOLIO

14.15.3 RECENT DEVELOPMENTS

14.16 NATERA, INC.

14.16.1 COMPANY SNAPSHOT

14.16.2 REVENUE ANALYSIS

14.16.3 PRODUCT PORTFOLIO

14.16.4 RECENT DEVELOPMENTS

14.17 NEXT BIOSCIENCES

14.17.1 COMPANY SNAPSHOT

14.17.2 PRODUCT PORTFOLIO

14.17.3 RECENT DEVELOPMENTS

14.18 NOVUS BIOLOGICALS (A SUBSIDIARY OF BIO-TECHNE)

14.18.1 COMPANY SNAPSHOT

14.18.2 REVENUE ANALYSIS

14.18.3 PRODUCT PORTFOLIO

14.18.4 RECENT DEVELOPMENT

14.19 KID SENSE CHILD DEVELOPMENT CORPORATION PTY LTD

14.19.1 COMPANY SNAPSHOT

14.19.2 SERVICE PORTFOLIO

14.19.3 RECENT DEVELOPMENT

14.2 PHYSIO.CO.UK.

14.20.1 COMPANY SNAPSHOT

14.20.2 SERVICE PORTFOLIO

14.20.3 RECENT DEVELOPMENT

14.21 SYMBOL

14.21.1 COMPANY SNAPSHOT

14.21.2 SERVICE PORTFOLIO

14.21.3 RECENT DEVELOPMENT

15 QUESTIONNAIRE

16 RELATED REPORTS

Lista de Tabela

LIST OF TABLES

TABLE 1 ASIA-PACIFIC DOWN SYNDROME MARKET: PIPELINE ANALYSIS

TABLE 2 REGULATION IMPOSED BY SEVERAL REGULATORY AGENCIES IN DIFFERENT REGIONS

TABLE 3 ASIA-PACIFIC DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 4 ASIA-PACIFIC TRISOMY 21 IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 ASIA-PACIFIC TRANSLOCATION DOWN SYNDROME IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 ASIA-PACIFIC MOSAIC DOWN SYNDROME IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 ASIA-PACIFIC DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 8 ASIA-PACIFIC DIAGNOSIS IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 9 ASIA-PACIFIC DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 10 ASIA-PACIFIC DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 11 ASIA-PACIFIC FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 12 ASIA-PACIFIC INTEGRATED SCREENING TEST IN DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 13 ASIA-PACIFIC DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 14 ASIA-PACIFIC THERAPY IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 15 ASIA-PACIFIC THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 16 ASIA-PACIFIC EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 17 ASIA-PACIFIC ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 18 ASIA-PACIFIC SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 19 ASIA-PACIFIC THERAPY IN DOWN SYNDROM MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 20 ASIA-PACIFIC HOSPITAL IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 21 ASIA-PACIFIC CLINICS IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 22 ASIA-PACIFIC HOMECARE SETTING IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 ASIA-PACIFIC THERAPY CENTERS IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 24 ASIA-PACIFIC OTHERS IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 ASIA-PACIFIC DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 26 ASIA-PACIFIC DIRECT TENDER IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 ASIA-PACIFIC RETAIL SALES IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 28 ASIA-PACIFIC OTHERS IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 ASIA-PACIFIC DOWN SYNDROME MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 30 ASIA-PACIFIC DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 31 ASIA-PACIFIC DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 32 ASIA-PACIFIC DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 33 ASIA-PACIFIC SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 34 ASIA-PACIFIC FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 35 ASIA-PACIFIC INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 36 ASIA-PACIFIC DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 37 ASIA-PACIFIC THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 38 ASIA-PACIFIC EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 39 ASIA-PACIFIC ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 40 ASIA-PACIFIC SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 41 ASIA-PACIFIC DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 42 ASIA-PACIFIC DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 43 CHINA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 44 CHINA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 45 CHINA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 46 CHINA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 47 CHINA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 48 CHINA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 49 CHINA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 50 CHINA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 51 CHINA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 52 CHINA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 53 CHINA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 54 CHINA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 55 CHINA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 56 JAPAN DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 57 JAPAN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 58 JAPAN DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 59 JAPAN SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 60 JAPAN FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 61 JAPAN INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 62 JAPAN DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 63 JAPAN THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 64 JAPAN EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 65 JAPAN ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 66 JAPAN SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 67 JAPAN DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 68 JAPAN DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 69 AUSTRALIA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 70 AUSTRALIA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 71 AUSTRALIA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 72 AUSTRALIA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 73 AUSTRALIA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 74 AUSTRALIA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 75 AUSTRALIA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 76 AUSTRALIA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 77 AUSTRALIA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 78 AUSTRALIA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 79 AUSTRALIA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 80 AUSTRALIA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 81 AUSTRALIA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 82 SOUTH KOREA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 83 SOUTH KOREA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 84 SOUTH KOREA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 85 SOUTH KOREA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 86 SOUTH KOREA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 87 SOUTH KOREA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 88 SOUTH KOREA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 89 SOUTH KOREA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 90 SOUTH KOREA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 91 SOUTH KOREA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 92 SOUTH KOREA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 93 SOUTH KOREA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 94 SOUTH KOREA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 95 INDIA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 96 INDIA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 97 INDIA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 98 INDIA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 99 INDIA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 100 INDIA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 101 INDIA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 102 INDIA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 103 INDIA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 104 INDIA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 105 INDIA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 106 INDIA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 107 INDIA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 108 SINGAPORE DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 109 SINGAPORE DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 110 SINGAPORE DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 111 SINGAPORE SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 112 SINGAPORE FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 113 SINGAPORE INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 114 SINGAPORE DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 115 SINGAPORE THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 116 SINGAPORE EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 117 SINGAPORE ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 118 SINGAPORE SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 119 SINGAPORE DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 120 SINGAPORE DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 121 THAILAND DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 122 THAILAND DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 123 THAILAND DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 124 THAILAND SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 125 THAILAND FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 126 THAILAND INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 127 THAILAND DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 128 THAILAND THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 129 THAILAND EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 130 THAILAND ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 131 THAILAND SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 132 THAILAND DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 133 THAILAND DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 134 MALAYSIA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 135 MALAYSIA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 136 MALAYSIA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 137 MALAYSIA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 138 MALAYSIA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 139 MALAYSIA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 140 MALAYSIA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 141 MALAYSIA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 142 MALAYSIA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 143 MALAYSIA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 144 MALAYSIA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 145 MALAYSIA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 146 MALAYSIA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 147 INDONESIA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 148 INDONESIA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 149 INDONESIA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 150 INDONESIA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 151 INDONESIA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 152 INDONESIA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 153 INDONESIA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 154 INDONESIA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 155 INDONESIA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 156 INDONESIA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 157 INDONESIA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 158 INDONESIA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 159 INDONESIA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 160 PHILIPPINES DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 161 PHILIPPINES DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 162 PHILIPPINES DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 163 PHILIPPINES SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 164 PHILIPPINES FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 165 PHILIPPINES INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 166 PHILIPPINES DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 167 PHILIPPINES THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 168 PHILIPPINES EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 169 PHILIPPINES ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 170 PHILIPPINES SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 171 PHILIPPINES DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 172 PHILIPPINES DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 173 VIETNAM DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 174 VIETNAM DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 175 VIETNAM DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 176 VIETNAM SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 177 VIETNAM FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 178 VIETNAM INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 179 VIETNAM DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 180 VIETNAM THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 181 VIETNAM EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 182 VIETNAM ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 183 VIETNAM SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 184 VIETNAM DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 185 VIETNAM DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 186 REST OF ASIA-PACIFIC DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

 

Lista de Figura

LIST OF FIGURES

FIGURE 1 ASIA-PACIFIC DOWN SYNDROME MARKET: SEGMENTATION

FIGURE 2 ASIA-PACIFIC DOWN SYNDROME MARKET : DATA TRIANGULATION

FIGURE 3 ASIA-PACIFIC DOWN SYNDROME MARKET: DROC ANALYSIS

FIGURE 4 ASIA-PACIFIC DOWN SYNDROME MARKET: ASIA-PACIFIC VS. REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA-PACIFIC DOWN SYNDROME MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA-PACIFIC DOWN SYNDROME MARKET: MULTIVARIATE MODELLING

FIGURE 7 ASIA-PACIFIC DOWN SYNDROME MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 ASIA-PACIFIC DOWN SYNDROME MARKET: DBMR MARKET POSITION GRID

FIGURE 9 ASIA-PACIFIC DOWN SYNDROME MARKET: MARKET END USER COVERAGE GRID

FIGURE 10 ASIA-PACIFIC DOWN SYNDROME MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 ASIA-PACIFIC DOWN SYNDROME MARKET: SEGMENTATION

FIGURE 12 INCREASING PREVALENCE OF DOWN SYNDROME AND OTHER RELATED DISORDERS AND RISING DEMAND FOR EFFECTIVE THERAPIES IS DRIVING THE ASIA-PACIFIC DOWN SYNDROME MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 TRISOMY 21 SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC DOWN SYNDROME MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA-PACIFIC DOWN SYNDROME MARKET

FIGURE 15 ASIA-PACIFIC DOWN SYNDROME MARKET: BY DISEASE TYPE, 2020

FIGURE 16 ASIA-PACIFIC DOWN SYNDROME MARKET: BY DISEASE TYPE, 2020-2028 (USD MILLION)

FIGURE 17 ASIA-PACIFIC DOWN SYNDROME MARKET: BY DISEASE TYPE, CAGR (2020-2028)

FIGURE 18 ASIA-PACIFIC DOWN SYNDROME MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 1 ASIA-PACIFIC DOWN SYNDROME MARKET: BY TREATMENT, 2020

FIGURE 2 ASIA-PACIFIC DOWN SYNDROME MARKET: BY TREATMENT, 2020-2028 (USD MILLION).

FIGURE 3 ASIA-PACIFIC DOWN SYNDROME MARKET: BY TREATMENT, CAGR (2020-2028)

FIGURE 4 ASIA-PACIFIC DOWN SYNDROME MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 5 ASIA-PACIFIC DOWN SYNDROME MARKET: BY END USER, 2020

FIGURE 6 ASIA-PACIFIC DOWN SYNDROME MARKET: BY END USER, 2020-2028 (USD MILLION)

FIGURE 7 ASIA-PACIFIC DOWN SYNDROME MARKET: BY END USER, CAGR (2020-2028)

FIGURE 8 ASIA-PACIFIC DOWN SYNDROME MARKET: BY END USER, LIFELINE CURVE

FIGURE 9 ASIA-PACIFIC DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 10 ASIA-PACIFIC DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

FIGURE 11 ASIA-PACIFIC DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)

FIGURE 12 ASIA-PACIFIC DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 13 ASIA-PACIFIC DOWN SYNDROME MARKET: SNAPSHOT (2020)

FIGURE 14 ASIA-PACIFIC DOWN SYNDROME MARKET: BY COUNTRY (2020)

FIGURE 15 ASIA-PACIFIC DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028)

FIGURE 16 ASIA-PACIFIC DOWN SYNDROME MARKET: BY COUNTRY (2021 - 2028)

FIGURE 17 ASIA-PACIFIC DOWN SYNDROME MARKET: BY TREATMENT (2021 & 2028)

FIGURE 18 ASIA-PACIFIC DOWN SYNDROME MARKET: COMPANY SHARE 2020 (%)

 

View Detailed Information Right Arrow

Metodologia de Investigação

A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados ​​e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.

A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis ​​de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.

Personalização disponível

A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.